Antiphospholipid syndrome: 30 years and our contribution

International Journal of Rheumatic Diseases

Volumn 18, Issue 2, 2015, Pages 233-241

  Koike, Takao ^a,b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NTT CORPORATION   (Japan)

Author keywords

Antiphospholipid antibody syndrome; Disease etiology and pathogenesis human

Indexed keywords

ANGIOSTATIN; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; EPITOPE; LUPUS ANTICOAGULANT; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; POLYSTYRENE; PROTHROMBIN; PROTHROMBIN ANTIBODY; STAT4 PROTEIN;

ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ANTIGENICITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL ACTIVATION; CLINICAL FEATURE; COMPLEMENT ACTIVATION; CONFORMATIONAL TRANSITION; CROSS LINKING; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY STUDY; FIBRINOLYSIS; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; INTRACELLULAR SIGNALING; NEGATIVE FEEDBACK; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN IMMOBILIZATION; PROTEIN POLYMORPHISM; RADIOIMMUNOASSAY; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SYPHILIS; SYPHILIS SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; EPIDEMIOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOUSE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; COMPLEMENT ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; PROGNOSIS; RISK ASSESSMENT;

EID: 84927913215     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12438     Document Type: Article

References (55)

1. Hughes GR (1983) Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 287, 1088-9.
2. Harris EN, Gharavi AE, Boey ML et al. (1983) Anti-cardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet, ii, 1211-4.
3. Koike T, Sueishi M, Funaki H, Tomioka H, Yoshida S (1984) Antiphospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 56, 193-9.
4. Harris EN, Gharavi AE, Loizou S et al. (1985) Crossreactivity of antiphospholipid antibodies. J Clin Lab Immunol 16, 1-6.
5. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA (1990) Anti-phospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87, 4120-4.
6. Galli M, Comfurius P, Maassen C et al. (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335, 952-3.
7. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T (1990) Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336, 177-8.
8. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T (1994) Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 179, 457-62.
9. Lozie J, Takahashi N, Putnam FW (1984) Complete amino acid sequence of human plasma β2-glycoprotein I. Proc Natl Acad Sci USA 81, 3640-4.
10. Kato H, Enjyoji K (1991) Amino acid sequence and location of the disulfide bonds in bovine β2-glycoprotein I: the presence of five Sushi domains. Biochemistry 30, 11687-94.
11. Matsuura E, Igarashi M, Igarashi Y et al. (1991) Molecular definition of human β2-glycoprotein I (β2-GPI) by cDNA cloning and inter species differences of β2-GPI in alternation anticardiolipin binding. Int Immunol 3, 1217-21.
12. Steinkasserer A, Estaller C, Weiss EH, Sim RB, Day AJ (1991) Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. Biochem J 277, 387-91.
13. Steinkasserer A, Dorner C, Wurzner R, Sim RB (1993) Human beta 2-glycoprotein I: molecular analysis of DNA and amino acid polymorphism. Hum Genet 91, 401-2.
14. Sanghera DK, Kristensen T, Hamman RF, Kamboh MI (1997) Molecular basis of the apolipoprotein H (β2-glycoprotein I) protein polymorphism. Hum Genet 100, 57-62.
15. Gushiken FC, Arnett FC, Ahn C, Thiagarajan P (1999) Polymorphism of beta2-glycoprotein I at codons 306 and 316 in patients with systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 42, 1189-93.
16. Yasuda S, Tustsumi A, Chiba H et al. (2000) beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 152, 337-46.
17. Takeuchi R, Atsumi T, Ieko M et al. (2000) Coagulation and fibrinolytic activities in 2 siblings with beta(2)-glycoprotein I deficiency. Blood 96, 1594-5.
18. Yasuda S, Atsumi T, Ieko M et al. (2004) Nicked beta2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 103, 3766-72.
19. Nakagawa H, Yasuda S, Matsuura E et al. (2009) Nicked β2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property. Blood 114, 2553-9.
20. Yoshida H, Fujiwara H, Fujiwara T, Ikehara S, Hamashima Y (1987) Quantitative analysis of myocardial infarction in (NZW x BXSB)F1 hybrid mice with systemic lupus erythematosus and small coronary artery disease. Am J Pathol 129, 477-85.
21. Hashimoto Y, Kawamura M, Ichikawa K et al. (1992) Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 149, 1063-8.
22. Matsuura E, Igarashi Y, Fujimoto M et al. (1992) Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 148, 3885-91.
23. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A (1996) Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 75, 721-4.
24. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T (1997) Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 77, 486-91.
25. Atsumi T, Ieko M, Bertolaccini ML et al. (2000) Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43, 1982-93.
26. Wu JR, Lentz BR (1994) Phospholipid-specific conformational changes in human prothrombin upon binding to procoagulant acidic lipid membranes. Thromb Haemost 71, 596-604.
27. Simmelink MJ, Horbach DA, Derksen RH et al. (2001) Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 113, 621-9.
28. Galli M, Ruggeri L, Barbui T (1998) Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 91, 1999-2004.
29. Sakai Y, Atsumi T, Ieko M et al. (2009) The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. Arthritis Rheum 60, 2457-67.
30. Raschi E, Testoni C, Bosisio D et al. (2003) Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101, 3495-500.
31. Meroni PL, Raschi E, Testoni C et al. (2001) Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 44, 2870-8.
32. Dunoyer-Geindre S, De Moerloose P, Galve-De Rochemonteix B, Reber G, Kruithof E (2002) NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2) glycoprotein 1 antibodies. Thromb Haemost 88, 851-7.
33. Bohgaki M, Atsumi T, Yamashita Y et al. (2004) The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 16, 1633-41.
34. Vega-Ostertag M, Harris EN, Pierangeli SS (2004) Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 50, 2911-9.
35. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS (2005) Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 52, 1545-54.
36. Sorice M, Longo A, Capozzi A et al. (2007) Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 56, 2687-97.
37. Nakajima K, Tohyama Y, Kohsaka S, Kurihara T (2004) Protein kinase C alpha requirement in the activation of p38 mitogen-activated protein kinase, which is linked to the induction of tumor necrosis factor alpha in lipopolysaccharide-stimulated microglia. Neurochem Int 44, 205-14.
38. Lopez-Pedrera C, Buendia P, Cuadrado MJ et al. (2006) Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 54, 301-11.
39. Girardi G, Redecha P, Salmon JE (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10, 1222-6.
40. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J (2005) Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 52, 2120-4.
41. Fischetti F, Durigutto P, Pellis V et al. (2005) Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 106, 2340-6.
42. Oku K, Atsumi T, Bohgaki M et al. (2009) Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68, 1030-5.
43. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A (1997) The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 185, 1619-27.
44. Girardi G (2010) Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome. Clin Rev Allergy Immunol 39, 160-5.
45. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376, 1498-509.
46. Meroni PL, Borghi MA, Raschi E, Tedesco F (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7, 330-9.
47. Atsumi T, Amengual O, Koike T (2011) Antiphospholipid syndrome: pathogenesis. In: Lahita RG, Tsokos G, Buyon J, Koike T (eds) Systemic Lupus Erythematosus, 5th edn, pp 945-65. Academic Press, San Diego, CA, USA.
48. Asherson RA, Doherty DG, Vergani D, Khamashta MA, Hughes GR (1992) Major histocompatibility complex associations with primary antiphospholipid syndrome. Arthritis Rheum 35, 124-5.
49. Camps MT, Cuadrado MJ, Ocon P et al. (1995) Association between HLA class II antigens and primary antiphospholipid syndrome from the south of Spain. Lupus 4, 51-5.
50. McHugh NJ, Maddison PJ (1989) HLA-DR antigens and anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 32, 1623-4.
51. Yasuda S, Atsumi T, Matsuura E et al. (2005) Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant. Arthritis Rheum 52, 212-8.
52. Kasahara H, Matsuura E, Kaihara K et al. (2005) Antigenic structures recognized by anti-beta2-glycoprotein I auto-antibodies. Int Immunol 17, 1533-42.
53. Horita T, Atsumi T, Yoshida N et al. (2009) STAT4 single nucleotide polymorphism, rs7574865 G/T, as a risk for antiphospholipid syndrome. Ann Rheum Dis 68, 1366-7.
54. Wilson WA, Gharavi AE, Koike T et al. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42, 1309-11.
55. Miyakis S, Lockshin MD, Atsumi T et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4, 295-306.